Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd., commonly referred to as Chugai, is a leading biopharmaceutical company headquartered in Tokyo, Japan. Established in 1925, Chugai has made significant strides in the pharmaceutical industry, particularly in the fields of oncology, immunology, and renal diseases. The company is renowned for its innovative research and development, focusing on the creation of novel therapeutic agents that address unmet medical needs. With a strong presence in Japan and expanding operations in Europe and the United States, Chugai has positioned itself as a key player in the global biopharmaceutical market. Its core products, including the pioneering monoclonal antibody therapies, are distinguished by their efficacy and safety profiles. Notably, Chugai has achieved remarkable milestones, such as the successful development of groundbreaking treatments that have transformed patient care.
DitchCarbon Score
How does Chugai Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Chugai Pharmaceutical Co's score of 46 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Chugai Pharmaceutical Co's reported carbon emissions
In 2023, Chugai Pharmaceutical Co., Ltd. reported total greenhouse gas emissions of approximately 1,000,000 kg CO2e, comprising 44,500,000 kg CO2e from Scope 1, 97,200,000 kg CO2e from Scope 2, and 1,000,000,000 kg CO2e from Scope 3 emissions. This reflects their ongoing commitment to addressing climate change. Chugai has set ambitious targets to significantly reduce its carbon footprint. The company aims to achieve a 60% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2030, using 2019 as the baseline year. Additionally, they plan to increase their annual sourcing of renewable electricity from 0% in 2019 to 100% by 2025. For Scope 3 emissions, Chugai is committed to a 30% reduction by 2030, also from a 2019 baseline. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit temperature rise to 1.5°C. Chugai's proactive approach underscores its dedication to sustainability within the pharmaceutical sector, reflecting a broader industry trend towards reducing carbon emissions and enhancing environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 47,300,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 65,500,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Chugai Pharmaceutical Co is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
